Aclarion Inc
ACON5.880USD
-0.110-1.84%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.42MMarket Cap
LossP/E TTM
More Details of Aclarion Inc Company
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Aclarion Inc Info
Ticker SymbolACON
Company nameAclarion Inc
IPO dateApr 22, 2022
CEONess (Brent)
Number of employees6
Security typeOrdinary Share
Fiscal year-endApr 22
Address8181 Arista Place
CityBROOMFIELD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80021
Phone18332752266
Websitehttps://aclarion.com/
Ticker SymbolACON
IPO dateApr 22, 2022
CEONess (Brent)
Company Executives of Aclarion Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.00
+333.33%
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Dr. Scott Breidbart, M.D.
Dr. Scott Breidbart, M.D.
Independent Director
Independent Director
--
--
Mr. David Neal
Mr. David Neal
Director
Director
--
--
Dr. Jeff Thramann, M.D.
Dr. Jeff Thramann, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Brent Ness
Mr. Brent Ness
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.00
+333.33%
Mr. Ryan Bond
Mr. Ryan Bond
Chief Strategy Officer
Chief Strategy Officer
1.00
--
Mr. Gregory A. (Greg) Gould
Mr. Gregory A. (Greg) Gould
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Steve Deitsch
Mr. Steve Deitsch
Independent Director
Independent Director
--
--
Ms. Amanda Williams
Ms. Amanda Williams
Independent Director
Independent Director
--
--
Mr. William Wesemann
Mr. William Wesemann
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
DRW Securities, LLC
1.72%
CAPTRUST Financial Advisors
1.49%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.31%
Tower Research Capital LLC
0.09%
Other
95.38%
Shareholders
Shareholders
Proportion
DRW Securities, LLC
1.72%
CAPTRUST Financial Advisors
1.49%
The Vanguard Group, Inc.
1.01%
Geode Capital Management, L.L.C.
0.31%
Tower Research Capital LLC
0.09%
Other
95.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.22%
Investment Advisor/Hedge Fund
0.31%
Hedge Fund
0.09%
Research Firm
0.04%
Other
95.35%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
15
31.25K
1.59%
--
2025Q3
15
31.25K
0.88%
+26.14K
2025Q2
9
2.11K
0.08%
+1.65K
2025Q1
16
366.00
0.00%
+366.00
2024Q4
14
--
0.00%
--
2024Q3
14
--
0.00%
--
2024Q2
21
--
0.00%
--
2024Q1
22
--
0.00%
--
2023Q4
21
--
0.00%
--
2023Q3
20
--
0.00%
--
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
1.71K
0.29%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
1.59K
0.27%
+610.00
+62.37%
Aug 31, 2025
Tower Research Capital LLC
75.00
0.01%
+72.00
+2400.00%
Jun 30, 2025
Ness (Brent)
3.00
0%
+3.00
--
May 09, 2025
Thramann (Jeffrey John)
10.00
0%
+10.00
--
May 09, 2025
BofA Global Research (US)
8.00
0%
+4.00
+100.00%
Jun 30, 2025
Clear Street LLC
3.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Date
Type
Ratio
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Mar 26, 2025
Merger
27→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 24, 2025
Merger
335→1
Jan 02, 2024
Merger
16→1
Jan 02, 2024
Merger
16→1
View more
FAQs
Who are the top five shareholders of Aclarion Inc?
The top five shareholders of Aclarion Inc are:
The Vanguard Group, Inc. holds 1.71K shares, accounting for 0.29% of the total shares.
Geode Capital Management, L.L.C. holds 1.59K shares, accounting for 0.27% of the total shares.
Tower Research Capital LLC holds 75.00 shares, accounting for 0.01% of the total shares.
Ness (Brent) holds 3.00 shares, accounting for 0.00% of the total shares.
Thramann (Jeffrey John) holds 10.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 1.71K shares, accounting for 0.29% of the total shares.
Geode Capital Management, L.L.C. holds 1.59K shares, accounting for 0.27% of the total shares.
Tower Research Capital LLC holds 75.00 shares, accounting for 0.01% of the total shares.
Ness (Brent) holds 3.00 shares, accounting for 0.00% of the total shares.
Thramann (Jeffrey John) holds 10.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Aclarion Inc?
The top three shareholder types of Aclarion Inc are:
DRW Securities, LLC
CAPTRUST Financial Advisors
The Vanguard Group, Inc.
DRW Securities, LLC
CAPTRUST Financial Advisors
The Vanguard Group, Inc.
How many institutions hold shares of Aclarion Inc (ACON)?
As of 2025Q4, 15 institutions hold shares of Aclarion Inc, with a combined market value of approximately 31.25K, accounting for 1.59% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.71%.
What is the biggest source of revenue for Aclarion Inc?
In --, the -- business generated the highest revenue for Aclarion Inc, amounting to -- and accounting for --% of total revenue.
